Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q3 2023 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and if they point to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Key points: - Management discusses their Investor Day, their growth, their strategies. - Jason Gottlieb discusses credit expansion, emerging markets, and distribution evolution. - They mention new hires, new funds, and strategies. - They discuss flows and performance. Specifically, they mention: - "We completed the first close of the Artisan dislocation opportunities fund." That's a concrete thing. - They onboarded institutional accounts in EM local opportunities, global unconstrained, and high income strategy had strong flows. - They talk about distribution evolution, hiring first individual to focus on marketing alternatives. - They talk about emerging markets being underweighted by allocators, but they are building out. Now, does management convey that outsiders are currently underweighting something the company has already done? That is, is there a recognition gap that management itself raises? Look for statements like "not yet appreciated", "still anchored to", "understate", "lag", etc. In the transcript, Eric Colson says: "We have expanded across more investment teams, asset classes and geographies. We have a repeatable process for identifying, recruiting, onboarding and partnering with investment talent. Our operational platform has more capabilities than ever. We are evolving our distribution model, and we have in place a business management team with deep industry and Artisan-specific experience that is extremely well positioned to move us forward." That's more of a general statement. Jason Gottlieb says: "We have demonstrated that our philosophy and process works for clients and talent beyond public equities. In short, these strategies have performed." That's about performance. They talk about emerging markets being underweighted by allocators, but that's about the asset class, not about the company itself being underweighted. Is there any statement that the market or analysts are not fully appreciating something? Possibly the distribution evolution? They say "We are evolving our distribution model" but that's a plan.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.